Organisation paid for research Program year 2025 Source: CMS Open Payments

Hing-Sheung Eugene Fung MD PA

Neither a doctor nor a teaching hospital

Research payments

$877,315

242 payments

Through program year 2025, Hing-Sheung Eugene Fung MD PA is reported as receiving $877,315 in research payments, across 242 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$19,453	6
2024	Research	$16,820	9
2023	Research	$56,250	25
2022	Research	$99,814	31
2021	Research	$203,492	56
2020	Research	$330,703	64
2019	Research	$150,784	51

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $456,468 177 payments
Ucb SA $296,572 15 payments
GlaxoSmithKline, LLC. $74,296 36 payments
Janssen Research & Development, LLC $38,345 11 payments
Argenx US, Inc. $11,634 3 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Pso $163,058 1 payment
M15-572 $87,122 20 payments
M15-554 $63,554 24 payments
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $62,740 8 payments
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) $55,988 18 payments
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) $55,680 21 payments
A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $50,268 28 payments
M13-549 $48,752 19 payments
M15-555 $44,013 19 payments
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent $38,345 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.